This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin And Management Of AbSSTI At ICAAC 2012

Durata Therapeutics (NASDAQ: DRTX) today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will be held in San Francisco, CA from September 9-12, 2012.

Sunday, September 9, 2012

  • Update of Dalbavancin (DAL) Activity in the USA: Report from the SENTRY Program (2011). (Jones, et al). Session Number: 010, Presentation Number: C2-138, 11:30 AM – 1:30 PM (Halls A-C)
  • Comparative In Vitro Activity of Dalbavancin (DAL) and Other Gram- Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134, 11:30 – 1:30 PM (Halls A-C).
  • Costs of Outpatient Parenteral Antibiotic Therapy (OPAT) for the Management of Gram+ Acute Bacterial Skin and Soft Tissue Infections (abSSTIs) (Khachatryan, et al). Session Number: 020, Presentation Number: K-239, 11:30 AM – 1:30 PM (Halls A-C)

Monday, September 10, 2012

  • A Single-Center, Randomized, Placebo- and Positive-Controlled, Parallel-Group Study of the Electrocardiographic Effects of Dalbavancin in Healthy Male and Female Subjects. (Dunne, et al). Session Number: 082, Presentation Number: A-623, 11:15 AM – 1:15 PM (Halls A-C)

Tuesday, September 11, 2012

  • A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and non-Fastidious Gram-Positive Organisms (Killian, et al). Session Number: 173, Presentation Number: E-1467, 11:15 AM- 1:15 PM (Halls A-C)

*Note: all times are listed in Pacific Time.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI, caused by Gram-positive bacteria, such as S. aureus, including Methicillin-Resistant and multi-drug resistant strains, and certain streptococcal species. The product candidate is a semi-synthetic lipoglycopeptide designed and under investigation for once-weekly intravenous dosing which may facilitate the treatment of patients with abSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.56 -50.12 -0.29%
S&P 500 1,990.55 -3.74 -0.19%
NASDAQ 4,524.9220 -2.7670 -0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs